170 related articles for article (PubMed ID: 29785311)
1. Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features.
Khan AM; Muzaffar J; Murthy H; Wingard JR; Moreb JS
Case Rep Hematol; 2018; 2018():9052314. PubMed ID: 29785311
[TBL] [Abstract][Full Text] [Related]
2. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Sinit RB; Hwang DG; Vishnu P; Peterson JF; Aboulafia DM
BMC Cancer; 2019 Nov; 19(1):1147. PubMed ID: 31775673
[TBL] [Abstract][Full Text] [Related]
3. Three Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL.
Vusqa UT; Chahine Z; Asawa P; Sadashiv S; Samhouri Y; Lister J
J Oncol Pharm Pract; 2022 Jul; 28(5):1214-1217. PubMed ID: 35060775
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance.
Liu J; Huang B; Gu J; Li J
J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983594
[No Abstract] [Full Text] [Related]
6. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
7. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial.
Jones JR; Cairns DA; Menzies T; Pawlyn C; Davies FE; Sigsworth R; Brioli A; Jenner MW; Kaiser MF; Olivier C; Reed M; Drayson MT; Owen RG; Boyd KD; Cook G; Morgan GJ; Jackson GH;
EClinicalMedicine; 2023 Aug; 62():102099. PubMed ID: 37554123
[TBL] [Abstract][Full Text] [Related]
8. Treatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma.
Crosby J; Erzuah T; Haider M; Smith F; Ganti S; Monohan G; Elsouiedi R
J Investig Med High Impact Case Rep; 2022; 10():23247096221133204. PubMed ID: 36300378
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
McCarthy PL; Holstein SA; Petrucci MT; Richardson PG; Hulin C; Tosi P; Bringhen S; Musto P; Anderson KC; Caillot D; Gay F; Moreau P; Marit G; Jung SH; Yu Z; Winograd B; Knight RD; Palumbo A; Attal M
J Clin Oncol; 2017 Oct; 35(29):3279-3289. PubMed ID: 28742454
[TBL] [Abstract][Full Text] [Related]
10. New developments in post-transplant maintenance treatment of multiple myeloma.
Liu H; McCarthy P
Semin Oncol; 2013 Oct; 40(5):602-9. PubMed ID: 24135405
[TBL] [Abstract][Full Text] [Related]
11. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.
Jagannath S; Abonour R; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Agarwal A; Srinivasan S; Kitali A; Flick ED; Sturniolo M; Rifkin RM
Blood Adv; 2018 Jul; 2(13):1608-1615. PubMed ID: 29986853
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
13. Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma.
Al-Mansour Z; Ramanathan M
Adv Hematol; 2014; 2014():652395. PubMed ID: 25525435
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
[TBL] [Abstract][Full Text] [Related]
15. Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant.
LeBlanc R; Hollmann S; Tay J
J Popul Ther Clin Pharmacol; 2016; 23(1):e103-13. PubMed ID: 27337740
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Richardson PG; Holstein SA; Schlossman RL; Anderson KC; Attal M; McCarthy PL
Expert Opin Pharmacother; 2017 Dec; 18(18):1975-1985. PubMed ID: 29172855
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.
Al-Ani F; Louzada M
Eur J Haematol; 2017 Dec; 99(6):479-488. PubMed ID: 28885719
[TBL] [Abstract][Full Text] [Related]
18. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
[TBL] [Abstract][Full Text] [Related]
19. The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Pan B; Lentzsch S
Pharmacol Ther; 2012 Oct; 136(1):56-68. PubMed ID: 22796518
[TBL] [Abstract][Full Text] [Related]
20. Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Gössi U; Jeker B; Mansouri Taleghani B; Bacher U; Novak U; Betticher D; Egger T; Zander T; Pabst T
Hematol Oncol; 2018 Apr; 36(2):436-444. PubMed ID: 29363149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]